(Q39329007)

11 September 2017

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). (English)

1 reference

11 September 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

M T Gómez-Casares

1

1 reference

11 September 2017

E García-Alegria

2

1 reference

11 September 2017

C E López-Jorge

3

1 reference

11 September 2017

N Ferrándiz

4

1 reference

11 September 2017

R Blanco

5

1 reference

11 September 2017

S Alvarez

6

1 reference

11 September 2017

J P Vaqué

7

1 reference

11 September 2017

G Bretones

8

1 reference

11 September 2017

J M Caraballo

9

1 reference

11 September 2017

P Sánchez-Bailón

10

1 reference

11 September 2017

M D Delgado

11

1 reference

11 September 2017

J Martín-Perez

12

1 reference

11 September 2017

J C Cigudosa

13

1 reference

11 September 2017

J León

14

1 reference

11 September 2017

language of work or name

English

0 references

publication date

18 June 2012

1 reference

11 September 2017

1 reference

11 September 2017

32

1 reference

11 September 2017

2239-2246

1 reference

11 September 2017

17

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.246

11 September 2017

0 references

cites work

The c-Myc target gene network

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

MYC oncogenes and human neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

The Myc oncoprotein as a therapeutic target for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Reflecting on 25 years with MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Chronic myeloid leukaemia as a model of disease evolution in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Getting to the stem of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Chronic myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Recent advancements in the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Skp2-mediated degradation of p27 regulates progression into mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Skp2-dependent degradation of p27kip1 is essential for cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

Mxi1 is a repressor of the c-Myc promoter and reverses activation by USF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.246

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.246

1 reference

Dimensions Publication ID

11 September 2017

0 references

1 reference